Sirtex’s SARAH study is a Phase III multi-centre prospective randomised open-label study for patients in France with advanced hepatocellular carcinoma (HCC).
HCC is the most common form of primary liver cancer, a cancer that starts in the liver.
The SARAH study will be presented at the International Liver Congress on Saturday, 22nd April 2017.
The SARAH study directly compares Sirtex’s SIR-Spheres® Y-90 resin microspheres versus the current standard-of-care systemic therapy, sorafenib.
SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via selective internal radiation therapy (SIRT), directly to liver tumours.
The devices are approved for supply in key markets, such as the U.S., European Union and Australia.
The primary endpoint of the SARAH study is overall survival with secondary endpoints including safety and tolerability, tumour response rates and quality of life scores.
SARAH is the largest randomised study ever to compare selective internal radiation therapy using SIR-Spheres microspheres against the standard-of-care systemic therapy in the treatment of HCC.